Biomarkers France: a first and distinctive step in assessing the impact of non-small cell lung cancer (NSCLC) patients routine molecular profiling

The French Cooperative Thoracic Intergroup (IFCT) recently published the results of the Biomarkers France study, the largest nationwide program of molecular profiling for non-small cell lung cancer (NSCLC) patients (1). As highlighted in the three editorials published by Translational Cancer Research regarding these results, the Biomarkers France study not only shows that a routine molecular profiling is already feasible for all of our advanced NSCLC patients, but also that identification of a molecular alteration changes their outcomes by decreasing their risk of death by 22%.